Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FcRn Antagonists (Efgartigimod) for Acute Neuromyelitis Optica Spectrum Disorders (NMOSD) Attack: a Phase 2, Randomized Controlled Trial.

NCT06497374 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.

NCT NCT06497374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06497374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FcRn Antagonists (Efgartigimod) for Acute Neuromyelitis Optica Spectrum Disorders (NMOSD) Attack: a Phase 2, Randomized Controlled Trial.
Lead sponsor
Tianjin Medical University General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
July 5, 2024
Completion date
June 30, 2026
Enrollment
63 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica, neuromyelitis optica spectrum disorder, nmo spectrum disorder